Bumper Offer - Urjas oil Just @ Rs. 1
Zifi 50 DT Tablet (10) is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of Ear Infection, Tonsillitis, Bronchitis. Secondary and off-label uses of Zifi 50 DT Tablet (10) have also been mentioned below.
The right dosage of Zifi 50 DT Tablet (10) depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Some other side effects of Zifi 50 DT Tablet (10) have been listed ahead. These side effects of Zifi 50 DT Tablet (10) are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Zifi 50 DT Tablet (10) is Safe for pregnant women and Safe for women who are breastfeeding. Warnings related to Zifi 50 DT Tablet (10)'s effects on the liver, heart and kidney, if any, have been listed below.
Other contraindications of Zifi 50 DT Tablet (10) have been discussed in the sections ahead.
Drug reaction of Zifi 50 DT Tablet (10) with other medicines has been reported. Refer to the list below for further details.
In addition to the above precautions for Zifi 50 DT Tablet (10), it is important to know that it is not safe while driving, and is not habit-forming.
Zifi 50 DT Tablet (10) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Adult(Female) |
|
| 13 - 18 years (Adolescent) |
|
Is the use of Zifi 50 DT Tablet (10) safe for pregnant women?
Zifi is safe to take during pregnancy.
Is the use of Zifi 50 DT Tablet (10) safe during breastfeeding?
Zifi is completely safe for breastfeeding women.
What is the effect of Zifi 50 DT Tablet (10) on the Kidneys?
Zifi has very mild side effects on the kidneys.
What is the effect of Zifi 50 DT Tablet (10) on the Liver?
Zifi is not harmful for the liver.
What is the effect of Zifi 50 DT Tablet (10) on the Heart?
You can take Zifi without any fear of damage to the heart.
Zifi 50 DT Tablet (10) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Zifi 50 DT Tablet (10) unless your doctor advises you to do so -
Is this Zifi 50 DT Tablet (10) habit forming or addictive?
No, you will not get addicted to Zifi 50 DT Tablet (10).
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Zifi 50 DT Tablet (10) as you may feel sleepy.
Is it safe?
Zifi 50 DT Tablet (10) is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, the use of Zifi 50 DT Tablet (10) in mental disorders is not effective.
Interaction between Food and Zifi 50 DT Tablet (10)
Taking Zifi 50 DT Tablet (10) with food does not cause any problems.
Interaction between Alcohol and Zifi 50 DT Tablet (10)
It is difficult to say anything about the effect of Zifi 50 DT Tablet (10) and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 839
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-309
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Suprax® (cefixime)
